Cipla报告说,尽管对美国关税和药品价格订单有所顾虑,但Q4的利润仍大幅上升。 Cipla reports a significant Q4 profit rise despite concerns over US tariffs and drug price orders.

印度制药公司Cipla报告,Q4净利润增加30%,达到1 222卢比,收入增加9%,达到6 730卢比。 Cipla, an Indian pharmaceutical company, reported a 30% rise in Q4 net profit to Rs 1,222 crore and a 9% increase in revenue to Rs 6,730 crore. 该公司的首席执行官Umang Vohra说,预期美国潜在的关税和Trump关于药物价格的订单不会对Cipla产生直接影响。 The company's CEO, Umang Vohra, stated that potential US tariffs and Trump's order on drug prices are not expected to have an immediate impact on Cipla. 公司董事会批准了每股16卢比的红利,标志着该公司成立90周年。 The company's board approved a dividend of Rs 16 per share, marking its 90th anniversary. 25财政年度,Cipla的净利润增加了28%,达到5,272卢比。 For FY25, Cipla saw a 28% increase in net profit to Rs 5,272 crore.